Xin Qiu

State Key Laboratory Of Severe Weather Meteorological Science And Technology
Nanjing, 210023, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Archeological data with AI- and physics-based modeling explain typhoon-induced disasters in inland China around 3000 yr B.P.

Archeological data with AI- and physics-based modeling explain typhoon-induced disasters in inland China around 3000 yr B.P.

Journal: Science advances

Published: March 04, 2026

Efficacy and safety of second-line therapy by S-1 combined with sintilimab and anlotinib in pancreatic cancer patients with liver metastasis: a single-arm, phase II clinical trial.

Efficacy and safety of second-line therapy by S-1 combined with sintilimab and anlotinib in pancreatic cancer patients with liver metastasis: a single-arm, phase II clinical trial.

Journal: Frontiers in immunology

Published: April 23, 2023

Biomarkers for predicting tumor response to PD-1 inhibitors in patients with advanced pancreatic cancer.

Biomarkers for predicting tumor response to PD-1 inhibitors in patients with advanced pancreatic cancer.

Journal: Human vaccines & immunotherapeutics

Published: February 22, 2023

Efficacy and safety of immune checkpoint inhibitors in advanced pancreatic cancer: A real world study in Chinese cohort.

Efficacy and safety of immune checkpoint inhibitors in advanced pancreatic cancer: A real world study in Chinese cohort.

Journal: Human vaccines & immunotherapeutics

Published: November 22, 2022

PD-1 blockade plus chemoradiotherapy as preoperative therapy for patients with BRPC/LAPC: A biomolecular exploratory, phase II trial.

PD-1 blockade plus chemoradiotherapy as preoperative therapy for patients with BRPC/LAPC: A biomolecular exploratory, phase II trial.

Journal: Cell reports. Medicine

Published: October 24, 2022

Case Report: Pathologic Complete Response to Induction Therapy in a Patient With Potentially Resectable Pancreatic Cancer.

Case Report: Pathologic Complete Response to Induction Therapy in a Patient With Potentially Resectable Pancreatic Cancer.

Journal: Frontiers in oncology

Published: March 17, 2022

Study protocol for a prospective, open-label, single-arm, phase II study on the combination of tislelizumab, nab-paclitaxel, gemcitabine, and concurrent radiotherapy as the induction therapy for patients with locally advanced and borderline resectable pancreatic cancer.

Study protocol for a prospective, open-label, single-arm, phase II study on the combination of tislelizumab, nab-paclitaxel, gemcitabine, and concurrent radiotherapy as the induction therapy for patients with locally advanced and borderline resectable pancreatic cancer.

Journal: Frontiers in oncology

Published: February 20, 2022

Molecular Landscape and Prognostic Biomarker Analysis of Advanced Pancreatic Cancer and Predictors of Treatment Efficacy of AG Chemotherapy.

Molecular Landscape and Prognostic Biomarker Analysis of Advanced Pancreatic Cancer and Predictors of Treatment Efficacy of AG Chemotherapy.

Journal: Frontiers in oncology

Published: December 28, 2021

Advanced Pancreatic Cancer Patient Benefit From Personalized Neoantigen Nanovaccine Based Immunotherapy: A Case Report.

Advanced Pancreatic Cancer Patient Benefit From Personalized Neoantigen Nanovaccine Based Immunotherapy: A Case Report.

Journal: Frontiers in immunology

Published: October 21, 2021

Use of Nab-Paclitaxel Plus Gemcitabine Followed by Hypofractionated Tomotherapy With Simultaneous Integrated Boost in Patients With Locally Advanced Pancreatic Cancer.

Use of Nab-Paclitaxel Plus Gemcitabine Followed by Hypofractionated Tomotherapy With Simultaneous Integrated Boost in Patients With Locally Advanced Pancreatic Cancer.

Journal: Frontiers in oncology

Published: September 27, 2021

AGIG Chemo-Immunotherapy in Patients With Advanced Pancreatic Cancer: A Single-Arm, Single-Center, Phase 2 Study.

AGIG Chemo-Immunotherapy in Patients With Advanced Pancreatic Cancer: A Single-Arm, Single-Center, Phase 2 Study.

Journal: Frontiers in oncology

Published: April 10, 2021

A Pathological Brain Detection System based on Extreme Learning Machine Optimized by Bat Algorithm.

A Pathological Brain Detection System based on Extreme Learning Machine Optimized by Bat Algorithm.

Journal: CNS & neurological disorders drug targets

Published: February 24, 2016

Showing 1-12 of 12

Last Updated: 09/26/2026